Vanta Bioscience Financial Statements
Vanta Bioscience Balance Sheet
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar | Mar-2020 | - | - | - |
|---|---|---|---|---|
| Growth matrix (%) | ||||
| Revenue growth | -- | -- | -- | -- |
| Op profit growth | -- | -- | -- | -- |
| EBIT growth | -- | -- | -- | -- |
| Net profit growth | -- | -- | -- | -- |
| Profitability ratios (%) | ||||
| OPM | 30.90 | -- | -- | -- |
| EBIT margin | 23.30 | -- | -- | -- |
| Net profit margin | 7.22 | -- | -- | -- |
| RoCE | -- | -- | -- | -- |
| RoNW | -- | -- | -- | -- |
| RoA | -- | -- | -- | -- |
| Per share ratios () | ||||
| EPS | 1.60 | -- | -- | -- |
| Dividend per share | -- | -- | -- | -- |
| Cash EPS | (0.30) | -- | -- | -- |
| Book value per share | 37.20 | -- | -- | -- |
| Valuation ratios | ||||
| P/E | 56.90 | -- | -- | -- |
| P/CEPS | (343) | -- | -- | -- |
| P/B | 2.45 | -- | -- | -- |
| EV/EBIDTA | 16.70 | -- | -- | -- |
| Payout (%) | ||||
| Dividend payout | -- | -- | -- | -- |
| Tax payout | (25) | -- | -- | -- |
| Liquidity ratios | ||||
| Debtor days | -- | -- | -- | -- |
| Inventory days | -- | -- | -- | -- |
| Creditor days | -- | -- | -- | -- |
| Leverage ratios | ||||
| Interest coverage | (1.70) | -- | -- | -- |
| Net debt / equity | 0.73 | -- | -- | -- |
| Net debt / op. profit | 3.93 | -- | -- | -- |
| Cost breakup () | ||||
| Material costs | (8.30) | -- | -- | -- |
| Employee costs | (36) | -- | -- | -- |
| Other costs | (25) | -- | -- | -- |
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar( In .Cr) | Mar-2020 | - | - | - |
|---|---|---|---|---|
| Revenue | 14.10 | -- | -- | -- |
| yoy growth (%) | -- | -- | -- | -- |
| Raw materials | (1.20) | -- | -- | -- |
| As % of sales | 8.34 | -- | -- | -- |
| Employee costs | (5.10) | -- | -- | -- |
| As % of sales | 35.90 | -- | -- | -- |
| Other costs | (3.50) | -- | -- | -- |
| As % of sales | 24.90 | -- | -- | -- |
| Operating profit | 4.37 | -- | -- | -- |
| OPM | 30.90 | -- | -- | -- |
| Depreciation | (1.20) | -- | -- | -- |
| Interest expense | (1.90) | -- | -- | -- |
| Other income | 0.11 | -- | -- | -- |
| Profit before tax | 1.34 | -- | -- | -- |
| Taxes | (0.30) | -- | -- | -- |
| Tax rate | (25) | -- | -- | -- |
| Minorities and other | 0.01 | -- | -- | -- |
| Adj. profit | 1.02 | -- | -- | -- |
| Exceptional items | -- | -- | -- | -- |
| Net profit | 1.02 | -- | -- | -- |
| yoy growth (%) | -- | -- | -- | -- |
| NPM | 7.22 | -- | -- | -- |
- Switch to
-
Tabular DataGraph
| Y/e 31 Mar ( In .Cr) | Mar-2020 | - | - | - |
|---|---|---|---|---|
| Profit before tax | 1.34 | -- | -- | -- |
| Depreciation | (1.20) | -- | -- | -- |
| Tax paid | (0.30) | -- | -- | -- |
| Working capital | -- | -- | -- | -- |
| Other operating items | -- | -- | -- | -- |
| Operating cashflow | -- | -- | -- | -- |
| Capital expenditure | -- | -- | -- | -- |
| Free cash flow | -- | -- | -- | -- |
| Equity raised | -- | -- | -- | -- |
| Investments | -- | -- | -- | -- |
| Debt financing/disposal | -- | -- | -- | -- |
| Dividends paid | -- | -- | -- | -- |
| Other items | -- | -- | -- | -- |
| Net in cash | -- | -- | -- | -- |
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar ( In .Cr) | Mar-2020 | Mar-2019 | - | - |
|---|---|---|---|---|
| Equity capital | 6.31 | 6.31 | -- | -- |
| Preference capital | -- | -- | -- | -- |
| Reserves | 17.20 | 15.90 | -- | -- |
| Net worth | 23.50 | 22.30 | -- | -- |
| Minority interest | ||||
| Debt | 17.40 | 13.30 | -- | -- |
| Deferred tax liabilities (net) | 0.59 | 0.40 | -- | -- |
| Total liabilities | 42.40 | 36.90 | -- | -- |
| Fixed assets | 27.80 | 21.60 | -- | -- |
| Intangible assets | ||||
| Investments | -- | 1.95 | -- | -- |
| Deferred tax asset (net) | -- | -- | -- | -- |
| Net working capital | 14.50 | 10.10 | -- | -- |
| Inventories | 14 | 9.24 | -- | -- |
| Inventory Days | 362 | -- | -- | -- |
| Sundry debtors | 1.39 | 1.56 | -- | -- |
| Debtor days | 35.90 | -- | -- | -- |
| Other current assets | 5.22 | 1.38 | -- | -- |
| Sundry creditors | (3.20) | (0.50) | -- | -- |
| Creditor days | 81.60 | -- | -- | -- |
| Other current liabilities | (3) | (1.60) | -- | -- |
| Cash | 0.20 | 3.27 | -- | -- |
| Total assets | 42.40 | 36.90 | -- | -- |
- Switch to
-
ConsolidatedStandalone
| Report not showing data |
|---|
QuickLinks for Vanta Bioscience Ltd.
